Probing Disaccharide Binding to Triplatin as Models for Tumor Cell Heparan Sulfate (GAG) Interactions.

In this study, we have used [1H, 15N] NMR spectroscopy to investigate the interactions of the trinuclear platinum anticancer drug triplatin (1) (1,0,1/t,t,t or BBR3464) with site-specific sulfated and carboxylated disaccharides. Specifically, the disaccharides GlcNS(6S)-GlcA (I) and GlcNS(6S)-IdoA(2S) (II) are useful models of longer-chain glycosaminoglycans (GAGs) such as heparan sulfate (HS). For both the reactions of 15N-1 with I and II, equilibrium conditions were achieved more slowly (65 h) compared to the reaction with the monosaccharide GlcNS(6S) (9 h). The data suggest both carboxylate and sulfate binding of disaccharide I to the Pt with the sulfato species accounting for <1% of the total species at equilibrium. The rate constant for sulfate displacement of the aqua ligand (kL2) is 4 times higher than the analogous rate constant for carboxylate displacement (kL1). There are marked differences in the equilibrium concentrations of the chlorido, aqua, and carboxy-bound species for reactions with the two disaccharides, notably a significantly higher concentration of carboxylate-bound species for II, where sulfate-bound species were barely detectable. The trend mirrors that reported for the corresponding dinuclear platinum complex 1,1/t,t, where the rate constant for sulfate displacement of the aqua ligand was 3 times higher than that for acetate. Also similar to what we observed for the reactions of 1,1/t,t with the simple anions, aquation of the sulfato group is rapid, and the rate constant k-L2 is 3 orders of magnitude higher than that for displacement of the carboxylate (k-L1). Molecular dynamics calculations suggest that extra hydrogen-bonding interactions with the more sulfated disaccharide II may prevent or diminish sulfate binding of the triplatin moiety. The overall results suggest that Pt-O donor interactions should be considered in any full description of platinum complex cellular chemistry.

[1]  N. Farrell,et al.  Substitution-inert polynuclear platinum complexes and Glycosaminoglycans: A molecular dynamics study of its non-covalent interactions. , 2022, Journal of inorganic biochemistry.

[2]  N. Farrell,et al.  Conformational Modulation of Iduronic Acid-Containing Sulfated Glycosaminoglycans by a Polynuclear Platinum Compound. Implications for Development of Antimetastatic Platinum Drugs. , 2020, Angewandte Chemie.

[3]  N. Farrell,et al.  Biological relevance of interaction of platinum drugs with O-donor ligands. , 2019, Inorganica chimica acta.

[4]  N. Farrell,et al.  Glycans as Ligands in Bioinorganic Chemistry. Probing the Interaction of a Trinuclear Platinum Anticancer Complex with Defined Monosaccharide Fragments of Heparan Sulfate. , 2019, Inorganic chemistry.

[5]  Daniel E Lee,et al.  Substitution-Inert Polynuclear Platinum Complexes as Metalloshielding Agents for Heparan Sulfate. , 2018, Chemistry.

[6]  N. Farrell,et al.  Comparison of Metal-Ammine Compounds Binding to DNA and Heparin. Glycans as Ligands in Bioinorganic Chemistry. , 2018, Inorganic chemistry.

[7]  Cui Hao,et al.  Heparan Sulfate and Chondroitin Sulfate Glycosaminoglycans Are Targeted by Bleomycin in Cancer Cells , 2017, Cellular Physiology and Biochemistry.

[8]  N. Farrell,et al.  Competitive formation of DNA linkage isomers by a trinuclear platinum complex and the influence of pre-association. , 2015, Dalton transactions.

[9]  J. Seelig,et al.  riDOM, a cell-penetrating peptide. Interaction with DNA and heparan sulfate. , 2013, The journal of physical chemistry. B.

[10]  N. Farrell,et al.  Heparan sulfate proteoglycan-mediated entry pathway for charged tri-platinum compounds: differential cellular accumulation mechanisms for platinum. , 2012, Molecular pharmaceutics.

[11]  N. Farrell,et al.  Chimeric platinum-polyamines and DNA binding. Kinetics of DNA interstrand cross-link formation by dinuclear platinum complexes with polyamine linkers. , 2012, Journal of the American Chemical Society.

[12]  Markus Christen,et al.  Architecture, implementation and parallelisation of the GROMOS software for biomolecular simulation , 2012, Comput. Phys. Commun..

[13]  Wilfred F. van Gunsteren,et al.  New functionalities in the GROMOS biomolecular simulation software , 2012, J. Comput. Chem..

[14]  Andreas P. Eichenberger,et al.  Definition and testing of the GROMOS force-field versions 54A7 and 54B7 , 2011, European Biophysics Journal.

[15]  T. Imai,et al.  Spectroscopic studies of interactions of chondroitin sulfates with cisplatin. , 2011, Carbohydrate research.

[16]  N. Farrell,et al.  Determination of the kinetic profile of a dinuclear platinum anticancer complex in the presence of sulfate: introducing a new tool for the expedited analysis of 2D [(1)H,( 15)N] HSQC NMR spectra. , 2010, Inorganic chemistry.

[17]  Nicholas P. Farrell,et al.  The phosphate clamp: a small and independent motif for nucleic acid backbone recognition , 2010, Nucleic Acids Res..

[18]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[19]  N. Farrell,et al.  A third mode of DNA binding: Phosphate clamps by a polynuclear platinum complex. , 2006, Journal of the American Chemical Society.

[20]  P. Sadler,et al.  Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy , 2006 .

[21]  Markus Christen,et al.  The GROMOS software for biomolecular simulation: GROMOS05 , 2005, J. Comput. Chem..

[22]  Roberto D. Lins,et al.  A new GROMOS force field for hexopyranose‐based carbohydrates , 2005, J. Comput. Chem..

[23]  N. Farrell,et al.  Effects of geometric isomerism in dinuclear platinum antitumor complexes on aquation reactions in the presence of perchlorate, acetate and phosphate , 2005, JBIC Journal of Biological Inorganic Chemistry.

[24]  J. Esko,et al.  The sweet and sour of cancer: glycans as novel therapeutic targets , 2005, Nature Reviews Cancer.

[25]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[26]  Chris Oostenbrink,et al.  A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force‐field parameter sets 53A5 and 53A6 , 2004, J. Comput. Chem..

[27]  N. Farrell,et al.  Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure. , 2004, Journal of the American Chemical Society.

[28]  N. Farrell,et al.  Kinetic and equilibria studies of the aquation of the trinuclear platinum phase II anticancer agent [(trans-PtCl(NH(3))(2))(2)(mu-trans-Pt(NH(3))(2)(NH(2)(CH(2))(6)NH(2))(2))](4+) (BBR3464). , 2002, Inorganic chemistry.

[29]  Vladimir Sklenar,et al.  Gradient-Tailored Water Suppression for 1H-15N HSQC Experiments Optimized to Retain Full Sensitivity , 1993 .

[30]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[31]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[32]  M. von Itzstein,et al.  Heparan sulfate analogues act as decoy receptors and efficiently block enterovirus 71 infection. , 2019, ACS infectious diseases.